Navigation Links
Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
Date:5/14/2009

Results show improved insulin sensitivity and lower glucose levels

without the side effects of current therapies

KALAMAZOO, Mich., May 14 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) announced today that its lead compound, MSDC-0160, can improve insulin sensitivity and lower blood glucose levels in humans without the side effects of current therapies when taken over a 28-day period, according to preliminary data derived from the company's Phase IIa clinical trial.

"This preliminary data confirms that a PPAR-sparing thiazolidinedione (TZD) can improve insulin sensitivity and lower glucose similar to a traditional TZD," said Dr. Jerry Colca, president and chief scientific officer of MSDC. "These results are contrary to the commonly accepted theory of how leading diabetes drugs work and support our theory surrounding PPAR-sparing TZDs that led us to develop this lead compound and our drug portfolio. These results further validate our ongoing development efforts with follow-on compounds." The company plans to file an Investigational New Drug Application with the Food and Drug Administration for a second-generation compound by the end of 2009.

Nearly 100 patients participated in this double-blind, placebo and active-controlled, multicenter clinical trial conducted in the United States. This Phase IIa clinical trial follows two successful Phase I trials that validated earlier indications of an improved pharmacokinetic and safety profile of MSDC-0160.

Similar to Actos, MSDC-0160 lowered the circulation of fatty acids and significantly increased good (HDL) cholesterol. Unlike Actos, MSDC-0160 did not decrease the levels of circulating blood cells and did not produce an increase in body weight.

Complications from the leading type 2 diabetic therapies include weight gain and edema as well as the potential for congestive heart failure and bone loss.

"Our drug development program focuses on a different molecular target," said Colca. "We believe that selective activation of the novel mitochondrial target will produce a significantly improved safety profile for individuals with type 2 diabetes. If the results of this study can be successfully extended to longer trials, we might be able to achieve our long-term goal of a therapeutic option that could be used early in the course of the disease to prevent the otherwise inexorable progression of diabetes and its complications."

Colca and Rolf Kletzien, two West Michigan scientists who are developing the MSDC drug portfolio of more than 100 analogs, have spent much of their careers working on treatments for type 2 diabetes. Colca also was instrumental in the early development of pioglitazone, the active ingredient in Actos, during his tenure with Upjohn Company.

"We are pleased that our lead compound performed so well in the Phase IIa study," said Mark Olesnavage, chief executive officer of MSDC. "The preliminary Phase IIa results match our pre-clinical studies that suggested that this compound can deliver significant metabolic benefit without some of the complications inherent in current therapies."

Additional safety and expanded efficacy data will be gathered in a 90-day, multinational Phase IIb study that is planned for late 2009.

According to the American Diabetes Association, approximately $1 in every 10 health care dollars spent is attributed to diabetes. While an estimated 17.9 million Americans have been diagnosed with diabetes, 6.3 million people (or nearly one in four) are unaware that they have the disease.

There were 1.6 million new cases of diabetes in the United States during 2007. This growth rate of 7 percent continues to outpace the population growth and has been described by many health care professionals as an epidemic.

Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.

The company's scientific strategy is built on a historical understanding of insulin-sensitizing thiazolidinediones (TZDs) and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.

    CONTACT:
    Nick Wasmiller
    Seyferth & Associates Inc.
    1-800-435-9539
    wasmiller@seyferthpr.com


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
2. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
3. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
4. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
5. NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
6. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
10. MedNet Solutions to Share Industry Expertise at the 13th Annual EDC & Beyond Conference in Orlando, FL
11. Facet Solutions, Inc. Expands U.S. Pivotal Study With Next Generation Implant System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):